NeuroDerm Ltd.
Quick facts
Marketed products
- Levodopa and carbidopa · Neurology
Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits premature conversion of levodopa in the periphery, allowing more to reach the brain.
Phase 3 pipeline
- ND0612 · Neurology
ND0612 is a subcutaneous infusion formulation of levodopa/carbidopa that continuously delivers dopamine precursor to the brain to treat motor symptoms of Parkinson's disease. - Oral IR-LD/CD · Neurology
Oral IR-LD/CD is a levodopa/carbidopa combination that increases dopamine levels in the brain by delivering levodopa with carbidopa, a decarboxylase inhibitor, to treat motor symptoms of Parkinson's disease. - Placebo for Oral IR-LD/CD
This drug is a placebo, meaning it has no active therapeutic effect.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about NeuroDerm Ltd.
What are NeuroDerm Ltd.'s marketed drugs?
Top marketed products include Levodopa and carbidopa.
What is NeuroDerm Ltd.'s pipeline?
NeuroDerm Ltd. has 3 drugs in Phase 3, 0 in Phase 2, 2 in Phase 1. Late-stage candidates include ND0612, Oral IR-LD/CD, Placebo for Oral IR-LD/CD.
Related
- Levodopa and carbidopa · Neurology
- Sector hub: All tracked pharma companies